Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis.
暂无分享,去创建一个
[1] Peter Riederer,et al. The relevance of iron in the pathogenesis of Parkinson’s disease , 2011, Journal of neurochemistry.
[2] M. Wessling-Resnick,et al. Attenuated Inflammatory Responses in Hemochromatosis Reveal a Role for Iron in the Regulation of Macrophage Cytokine Translation1 , 2008, The Journal of Immunology.
[3] M. Hentze,et al. Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. , 2008, Annual review of nutrition.
[4] E. Nemeth. Iron regulation and erythropoiesis , 2008, Current opinion in hematology.
[5] L. Silvestri,et al. A potential pathogenetic role of iron in Alzheimer's disease , 2008, Journal of cellular and molecular medicine.
[6] Clara Camaschella,et al. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. , 2008, Blood.
[7] B. Ghetti,et al. Expression of a Mutant Form of the Ferritin Light Chain Gene Induces Neurodegeneration and Iron Overload in Transgenic Mice , 2008, The Journal of Neuroscience.
[8] N. A. Georgiou,et al. Can Iron Chelators Influence the Progression of Atherosclerosis? , 2008, Hemoglobin.
[9] R. Mahley,et al. Detrimental effects of apolipoprotein E4: potential therapeutic targets in Alzheimer's disease. , 2007, Current Alzheimer research.
[10] G. Perry,et al. Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron. , 2007, Biochemistry.
[11] A. Pietrangelo. Hemochromatosis: An endocrine liver disease , 2007, Hepatology.
[12] Ya Ke,et al. Brain iron metabolism: Neurobiology and neurochemistry , 2007, Progress in Neurobiology.
[13] Elizabeta Nemeth,et al. Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. , 2007, Blood.
[14] G. Musci,et al. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI‐ceruloplasmin , 2007, The EMBO journal.
[15] H. Cario,et al. Recent developments in iron chelation therapy. , 2007, Klinische Padiatrie.
[16] G. Boysen,et al. Hereditary hemochromatosis genotypes and risk of ischemic stroke , 2007, Neurology.
[17] R. Tanzi,et al. The 5′-untranslated region of Parkinson's disease α-synuclein messengerRNA contains a predicted iron responsive element , 2007, Molecular Psychiatry.
[18] M. Pook,et al. GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. , 2006, Genomics.
[19] S. David,et al. Age-Related Changes in Iron Homeostasis and Cell Death in the Cerebellum of Ceruloplasmin-Deficient Mice , 2006, The Journal of Neuroscience.
[20] T. Moos,et al. Ferroportin in the postnatal rat brain: implications for axonal transport and neuronal export of iron. , 2006, Seminars in pediatric neurology.
[21] Robert B. Wilson. Iron dysregulation in Friedreich ataxia. , 2006, Seminars in pediatric neurology.
[22] E. Morgan,et al. Brain capillary endothelial cells mediate iron transport into the brain by segregating iron from transferrin without the involvement of divalent metal transporter 1 , 2006, Journal of neurochemistry.
[23] M. Hentze,et al. Iron homeostasis in the brain: complete iron regulatory protein 2 deficiency without symptomatic neurodegeneration in the mouse , 2006, Nature Genetics.
[24] J. Connor,et al. Moderate iron deficiency in infancy: Biology and behavior in young rats , 2006, Behavioural Brain Research.
[25] D. Stephan,et al. Preliminary demonstration of an allelic association of the IREB2 gene with Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.
[26] N. Andrews,et al. Cybrd1 (duodenal cytochrome b) is not necessary for dietary iron absorption in mice. , 2005, Blood.
[27] P. Højrup,et al. Identification of the receptor scavenging hemopexin-heme complexes. , 2005, Blood.
[28] G. Pinkus,et al. A mouse model of juvenile hemochromatosis. , 2005, The Journal of clinical investigation.
[29] K. C. K. Lloyd,et al. Movement disorders in the Hfe knockout mouse , 2005, Nutritional neuroscience.
[30] S. You,et al. Ferritin in atherosclerosis. , 2005, Clinica chimica acta; international journal of clinical chemistry.
[31] V. Subramaniam,et al. First phenotypic description of transferrin receptor 2 knockout mouse, and the role of hepcidin , 2005, Gut.
[32] J. Eschbach. Iron requirements in erythropoietin therapy. , 2005, Best practice & research. Clinical haematology.
[33] N. Andrews,et al. Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. , 2005, The Journal of clinical investigation.
[34] B. Halliwell,et al. The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. , 2005, Free radical biology & medicine.
[35] Y. Huang,et al. Iron loading increases cholesterol accumulation and macrophage scavenger receptor I expression in THP-1 mononuclear phagocytes. , 2005, Metabolism: clinical and experimental.
[36] A. Donovan,et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. , 2005, Cell metabolism.
[37] S. Sindel,et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. , 2005, International heart journal.
[38] P. Riederer,et al. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man , 2005, Journal of Neural Transmission.
[39] D. German,et al. Three-dimensional computer reconstruction of midbrain dopaminergic neuronal populations: From mouse to man , 2005, Journal of Neural Transmission.
[40] François Mach,et al. Inflammation and Atherosclerosis , 2004, Herz.
[41] R. Hawkins,et al. α‐Synuclein produces a long‐lasting increase in neurotransmitter release , 2004, The EMBO journal.
[42] E. Rossi,et al. Clinical penetrance of C282Y homozygous HFE haemochromatosis. , 2004, The Clinical biochemist. Reviews.
[43] J. Andersen,et al. Perspectives on MAO-B in aging and neurological disease , 2004, Molecular Neurobiology.
[44] V. Beneš,et al. Targeted mutagenesis of the murine IRP1 and IRP2 genes reveals context-dependent RNA processing differences in vivo. , 2004, RNA.
[45] Alberto Gatti,et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[46] Paul Henman. Targeted! , 2004 .
[47] M. Davies,et al. Direct Detection and Quantification of Transition Metal Ions in Human Atherosclerotic Plaques: Evidence for the Presence of Elevated Levels of Iron and Copper , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[48] M. Hentze,et al. Balancing Acts Molecular Control of Mammalian Iron Metabolism , 2004, Cell.
[49] H. Chertkow,et al. Evaluation of HFE (hemochromatosis) mutations as genetic modifiers in sporadic AD and MCI , 2004, Neurobiology of Aging.
[50] A. Smith,et al. Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer’s disease , 2004, Journal of Medical Genetics.
[51] Z. Sheng,et al. Expression of the iron transporter ferroportin in synaptic vesicles and the blood–brain barrier , 2004, Brain Research.
[52] M. Youdim,et al. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats , 2004, Neuropharmacology.
[53] K. Iwai,et al. Genetic ablations of iron regulatory proteins 1 and 2 reveal why iron regulatory protein 2 dominates iron homeostasis , 2004, The EMBO journal.
[54] E. Morgan,et al. The significance of the mutated divalent metal transporter (DMT1) on iron transport into the Belgrade rat brain , 2003, Journal of neurochemistry.
[55] Christopher Exley,et al. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. , 2004, Journal of Alzheimer's disease : JAD.
[56] A. Mackinnon,et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. , 2003, Archives of neurology.
[57] E. Hirsch,et al. Neuromelanin associated redox‐active iron is increased in the substantia nigra of patients with Parkinson's disease , 2003, Journal of neurochemistry.
[58] Heather A. O'Neill,et al. Yeast Frataxin Sequentially Chaperones and Stores Iron by Coupling Protein Assembly with Iron Oxidation* , 2003, Journal of Biological Chemistry.
[59] S. David,et al. Glycosylphosphatidylinositol-anchored Ceruloplasmin Is Required for Iron Efflux from Cells in the Central Nervous System* , 2003, Journal of Biological Chemistry.
[60] A. Bush. Copper, zinc, and the metallobiology of Alzheimer disease. , 2003, Alzheimer disease and associated disorders.
[61] T. Montine,et al. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[62] J. Connor,et al. Iron Deficiency Alters Iron Regulatory Protein and Iron Transport Protein Expression in the Perinatal Rat Brain , 2003, Pediatric Research.
[63] C. Franceschi,et al. Association between the HFE mutations and unsuccessful ageing: a study in Alzheimer's disease patients from Northern Italy , 2003, Mechanisms of Ageing and Development.
[64] Subramanian Rajagopalan,et al. Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease , 2003, Neuron.
[65] Z. Harris. Aceruloplasminemia , 2003, Journal of the Neurological Sciences.
[66] B. Halliwell,et al. Correlation of iron and zinc levels with lesion depth in newly formed atherosclerotic lesions. , 2003, Free radical biology & medicine.
[67] O. Combarros,et al. Interaction of the H63D Mutation in the Hemochromatosis Gene with the Apolipoprotein E Epsilon 4 Allele Modulates Age at Onset of Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.
[68] S. Mandel,et al. Genes and oxidative stress in parkinsonism: cDNA microarray studies. , 2003, Advances in neurology.
[69] Xudong Huang,et al. An Iron-responsive Element Type II in the 5′-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript* , 2002, The Journal of Biological Chemistry.
[70] G. London,et al. Iron Therapy, Advanced Oxidation Protein Products, and Carotid Artery Intima-Media Thickness in End-Stage Renal Disease , 2002, Circulation.
[71] V. Felitti,et al. Prevalence of coronary heart disease associated with HFE mutations in adults attending a health appraisal center. , 2002, The American journal of medicine.
[72] S. Mooney,et al. The Ferroxidase Activity of Yeast Frataxin* , 2002, The Journal of Biological Chemistry.
[73] M. Ebadi,et al. Deferoxamine Attenuates Iron-Induced Oxidative Stress and Prevents Mitochondrial Aggregation and α-Synuclein Translocation in SK-N-SH Cells in Culture , 2002, Developmental Neuroscience.
[74] E. Hirsch,et al. Lack of up‐regulation of ferritin is associated with sustained iron regulatory protein‐1 binding activity in the substantia nigra of patients with Parkinson's disease , 2002, Journal of neurochemistry.
[75] A. Hofman,et al. Mutations in the Hemochromatosis Gene (HFE) and Stroke , 2002, Stroke.
[76] Hironobu Naiki,et al. Iron (III) induces aggregation of hyperphosphorylated τ and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease , 2002 .
[77] M. Ristow,et al. The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. , 2002, Human molecular genetics.
[78] Jean-Pierre Julien,et al. Ceruloplasmin Regulates Iron Levels in the CNS and Prevents Free Radical Injury , 2002, The Journal of Neuroscience.
[79] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[80] D. Oakes,et al. Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients. , 2002, Blood cells, molecules & diseases.
[81] J. Connor,et al. Developmental changes in the expression of iron regulatory proteins and iron transport proteins in the perinatal rat brain , 2002, Journal of neuroscience research.
[82] C. Angelopoulos,et al. Transferrin C2 allele, haemochromatosis gene mutations, and risk for Alzheimer's disease , 2002, Journal of neurology, neurosurgery, and psychiatry.
[83] J. Adamec,et al. Physical evidence that yeast frataxin is an iron storage protein. , 2002, Biochemistry.
[84] F. Torti,et al. Regulation of ferritin genes and protein. , 2002, Blood.
[85] M. Frasier,et al. Magnesium Inhibits Spontaneous and Iron-induced Aggregation of α-Synuclein* , 2002, The Journal of Biological Chemistry.
[86] Alberto Gatti,et al. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease , 2002, FEBS letters.
[87] Hironobu Naiki,et al. Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. , 2002, Journal of neurochemistry.
[88] M. Frasier,et al. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. , 2002, The Journal of biological chemistry.
[89] N. Hattori,et al. Iron accumulation in the substantia nigra of autosomal recessive juvenile parkinsonism (ARJP). , 2001, Parkinsonism & related disorders.
[90] C. Beaumont,et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[91] J. Beard,et al. Iron deficiency decreases dopamine D1 and D2 receptors in rat brain , 2001, Pharmacology Biochemistry and Behavior.
[92] C. Morris,et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease , 2001, Nature Genetics.
[93] G. Annoni,et al. The hemochromatosis gene affects the age of onset of sporadic Alzheimer’s disease , 2001, Neurobiology of Aging.
[94] Michel Goedert,et al. Alpha-synuclein and neurodegenerative diseases , 2001, Nature Reviews Neuroscience.
[95] D. Allsop,et al. alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. , 2001, Free radical biology & medicine.
[96] D. Selkoe. Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.
[97] J. Melki,et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits , 2001, Nature Genetics.
[98] Kazuhiro Iwai,et al. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice , 2001, Nature Genetics.
[99] A. Friedman,et al. The current state of free radicals in Parkinson's disease. Nigral iron as a trigger of oxidative stress. , 2001, Advances in neurology.
[100] Xudong Huang,et al. Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. , 2008, Journal of neurochemistry.
[101] P. Riederer,et al. Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation? , 2000, Journal of Chemical Neuroanatomy.
[102] D. Selkoe,et al. Toward a Comprehensive Theory for Alzheimer's Disease. Hypothesis: Alzheimer's Disease Is Caused by the Cerebral Accumulation and Cytotoxicity of Amyloid β‐Protein , 2000, Annals of the New York Academy of Sciences.
[103] John Hardy,et al. The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity , 2000, The Journal of Neuroscience.
[104] M. Golub,et al. Chronic marginal iron intakes during early development in mice alter brain iron concentrations and behavior despite postnatal iron supplementation. , 2000, The Journal of nutrition.
[105] P Bélisle,et al. Iron stores and coronary artery disease: a clinical application of a method to incorporate measurement error of the exposure in a logistic regression model. , 2000, Journal of clinical epidemiology.
[106] A. Warren,et al. Are hereditary hemochromatosis mutations involved in Alzheimer disease? , 2000, American journal of medical genetics.
[107] M. Arca,et al. Haemochromatosis gene mutations and risk of coronary artery disease , 2000, European Journal of Human Genetics.
[108] K. Fischbeck,et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. , 2000, Human molecular genetics.
[109] C. Beaumont,et al. Early Embryonic Lethality of H Ferritin Gene Deletion in Mice* , 2000, The Journal of Biological Chemistry.
[110] J. Ramires,et al. C282Y mutation in the HLA-H Gene is Not a Risk Factor for Patients with Myocardial Infarction , 2000, Journal of cardiovascular risk.
[111] J. Cooper,et al. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. , 2000, Human molecular genetics.
[112] L. Petrucelli,et al. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[113] G. Perry,et al. Sequestration of iron by Lewy bodies in Parkinson’s disease , 2000, Acta Neuropathologica.
[114] E. Beutler,et al. The effect of transferrin polymorphisms on iron metabolism. , 1999, Blood cells, molecules & diseases.
[115] E. Masliah,et al. Role of Cytochrome c as a Stimulator of α-Synuclein Aggregation in Lewy Body Disease* , 1999, The Journal of Biological Chemistry.
[116] K. Jellinger,et al. Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease? , 1999, Life sciences.
[117] J. Sixma,et al. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. , 1999, Circulation.
[118] T. Lakka,et al. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation : a prospective cohort study in men in eastern Finland. , 1999, Circulation.
[119] J. Gitlin,et al. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[120] F. Foury. Low iron concentration and aconitase deficiency in a yeast frataxin homologue deficient strain , 1999, FEBS letters.
[121] A. Hofman,et al. Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. , 1999, The American journal of clinical nutrition.
[122] C. Leitão,et al. Does serum ferritin correlate with coronary angiography findings? , 1999, International journal of cardiology.
[123] Nancy Andrews,et al. Transferrin receptor is necessary for development of erythrocytes and the nervous system , 1999, Nature Genetics.
[124] P D Griffiths,et al. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. , 1999, Brain : a journal of neurology.
[125] E. Masliah,et al. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro , 1999 .
[126] L. Fenart,et al. Receptor-mediated Transcytosis of Lactoferrin through the Blood-Brain Barrier* , 1999, The Journal of Biological Chemistry.
[127] D. Radisky,et al. The Yeast Frataxin Homologue Mediates Mitochondrial Iron Efflux , 1999, The Journal of Biological Chemistry.
[128] Gregory J. Anderson,et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse , 1999, Nature Genetics.
[129] E. Masliah,et al. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. , 1999, Neuroreport.
[130] J C Rothwell,et al. Physiology and Anatomy of Possible Oscillators in the Central Nervous System , 2008, Movement disorders : official journal of the Movement Disorder Society.
[131] A. Lang,et al. New developments in understanding the etiology of Parkinson's disease and in its treatment , 1998, Current Opinion in Neurobiology.
[132] E. Morgan,et al. Evidence for low molecular weight, non‐transferrin‐bound iron in rat brain and cerebrospinal fluid , 1998, Journal of neuroscience research.
[133] S. Murayama,et al. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for α-synuclein , 1998, Neurology.
[134] M. Hentze,et al. Activation of iron regulatory protein-1 by oxidative stress in vitro. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[135] R. Hynes,et al. The combined role of P- and E-selectins in atherosclerosis. , 1998, The Journal of clinical investigation.
[136] S. Minoshima,et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.
[137] A. Lin,et al. Striatal dopamine dynamics are altered following an intranigral infusion of iron in adult rats. , 1998, Free radical biology & medicine.
[138] W. Sly,et al. HFE gene knockout produces mouse model of hereditary hemochromatosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[139] A. Lin,et al. Neuroprotection by S‐nitrosoglutathione of brain dopamine neurons from oxidative stress , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[140] P. Jenner,et al. Oxidative mechanisms in nigral cell death in Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.
[141] E. Hirsch,et al. Iron metabolism and Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.
[142] R. Krüger,et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.
[143] A. Terashi,et al. Association of transferrin C2 allele with late-onset Alzheimer’s disease , 1997, Human Genetics.
[144] G. Perry,et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[145] D. Meyers,et al. Possible association of a reduction in cardiovascular events with blood donation. , 1997, Heart.
[146] M. Bradbury. Transport of Iron in the Blood‐Brain‐Cerebrospinal Fluid System , 1997, Journal of neurochemistry.
[147] M. MacDonald,et al. Frataxin gene of Friedreich's ataxia is targeted to mitochondria , 1997, Annals of neurology.
[148] F. Foury,et al. Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria , 1997, FEBS letters.
[149] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[150] M. Pandolfo,et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. , 1997, Science.
[151] R. Wolff,et al. The Hemochromatosis Founder Mutation in HLA-H Disrupts β2-Microglobulin Interaction and Cell Surface Expression* , 1997, The Journal of Biological Chemistry.
[152] P. Libby,et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. , 1997, The American journal of pathology.
[153] H. Parving,et al. Population based study of rates of multiple pregnancies in denmark, 1980-94 , 1997, BMJ.
[154] S E Ide,et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.
[155] T. Shima,et al. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. , 1997, Free radical biology & medicine.
[156] C. Marsden,et al. Indices of oxidative stress in Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies. , 1997, Journal of neural transmission. Supplementum.
[157] G. Bartzokis,et al. MR evaluation of age-related increase of brain iron in young adult and older normal males. , 1997, Magnetic resonance imaging.
[158] L. Pascazio,et al. Echo color Doppler imaging of carotid vessels in hemodialysis patients: evidence of high levels of atherosclerotic lesions. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[159] P. Thong,et al. Increased iron in the substantia nigra of 6-OHDA induced parkinsonian rats: a nuclear microscopy study , 1996, Brain Research.
[160] M. Dehouck,et al. Receptor-Mediated Transcytosis of Transferrin through Blood-Brain Barrier Endothelial Cells , 1996 .
[161] P. Patel,et al. Friedreich's Ataxia: Autosomal Recessive Disease Caused by an Intronic GAA Triplet Repeat Expansion , 1996, Science.
[162] P. Thong,et al. Elemental changes in atherosclerotic lesions using nuclear microscopy. , 1996, Cellular and molecular biology.
[163] J. Araujo,et al. Iron overload augments the development of atherosclerotic lesions in rabbits. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[164] J. Connor,et al. A Quantitative Analysis of Isoferritins in Select Regions of Aged, Parkinsonian, and Alzheimer's Diseased Brains , 1995, Journal of neurochemistry.
[165] T. Sarna,et al. The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. , 1995, Biochimica et biophysica acta.
[166] Akihiko Iwai,et al. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.
[167] C. Marsden,et al. Complex I, Iron, and ferritin in Parkinson's disease substantia nigra , 1994, Annals of neurology.
[168] C. Olanow,et al. Progressive Changes in Striatal Dopaminergic Markers, Nigral Volume, and Rotational Behavior Following Iron Infusion into the Rat Substantia Nigra , 1994, Experimental Neurology.
[169] J. Gutteridge. Hydroxyl Radicals, Iron, Oxidative Stress, and Neurodegeneration a , 1994, Annals of the New York Academy of Sciences.
[170] R. Rauramaa,et al. Association of risk factors and body iron status to carotid atherosclerosis in middle-aged eastern Finnish men. , 1994, European heart journal.
[171] M. Vlad,et al. Concentration of copper, zinc, chromium, iron and nickel in the abdominal aorta of patients deceased with coronary heart disease. , 1994, Journal of trace elements and electrolytes in health and disease.
[172] N. Hattori,et al. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys , 1994, Neuroscience Letters.
[173] N. Seidah,et al. The family of subtilisin/kexin like pro-protein and pro-hormone convertases: divergent or shared functions. , 1994, Biochimie.
[174] A. D. Roses,et al. Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .
[175] W. Aronow. Serum ferritin is not a risk factor for coronary artery disease in men and women aged > or = 62 years. , 1993, The American journal of cardiology.
[176] D. Williamson,et al. Iron and ischemic heart disease. , 1993, Circulation.
[177] H. Macdonald. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. , 1993, Circulation.
[178] R. Ross. The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.
[179] C. Morris,et al. Iron and aluminium in relation to brain ferritin in normal individuals and Alzheimer's-disease and chronic renal-dialysis patients. , 1992, The Biochemical journal.
[180] O. Aruoma,et al. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. , 1992, The Biochemical journal.
[181] Heikki Korpela,et al. High Stored Iron Levels Are Associated With Excess Risk of Myocardial Infarction in Eastern Finnish Men , 1992, Circulation.
[182] C. Barrow,et al. Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. , 1992, Journal of molecular biology.
[183] N. Robakis,et al. Immunohistochemical evidence of antioxidant stress in Alzheimer's disease , 1992 .
[184] D. Perl,et al. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: A laser microprobe (LAMMA) study , 1992, Annals of neurology.
[185] J. Connor,et al. Regional distribution of iron and iron‐regulatory proteins in the brain in aging and Alzheimer's disease , 1992, Journal of neuroscience research.
[186] P. Riederer,et al. Iron‐Melanin Interaction and Lipid Peroxidation: Implications for Parkinson's Disease , 1991, Journal of neurochemistry.
[187] C. Barrow,et al. Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. , 1991, Science.
[188] D. McLachlan,et al. Intramuscular desferrioxamine in patients with Alzheimer's disease , 1991, The Lancet.
[189] C. Marsden,et al. Decreased Ferritin Levels in Brain in Parkinson's Disease , 1990, Journal of neurochemistry.
[190] M. Delong,et al. Primate models of movement disorders of basal ganglia origin , 1990, Trends in Neurosciences.
[191] A. J. Valente,et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[192] J. de Vellis,et al. Transferrin gene expression and secretion by rat brain cells in vitro , 1990, Journal of neuroscience research.
[193] A. Lusis,et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins , 1990, Nature.
[194] A J Barkovich,et al. Normal deposition of brain iron in childhood and adolescence: MR imaging at 1.5 T. , 1989, Radiology.
[195] F. Zemlan,et al. Superoxide dismutase activity in Alzheimer's disease: possible mechanism for paired helical filament formation , 1989, Brain Research.
[196] Bernstein Se. Hereditary hypotransferrinemia with hemosiderosis, a murine disorder resembling human atransferrinemia. , 1987 .
[197] S. E. Bernstein. Hereditary hypotransferrinemia with hemosiderosis, a murine disorder resembling human atransferrinemia. , 1987, The Journal of laboratory and clinical medicine.
[198] E. Larkin,et al. Effect of prenatal iron deficiency on myelination in rat pups. , 1986, The American journal of pathology.
[199] A. Chait,et al. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. , 1984, The Journal of clinical investigation.
[200] J. Sullivan. IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK , 1981, The Lancet.
[201] R. Hoeldtke,et al. Bovine adrenal tyrosine hydroxylase: purification and properties. , 1977, The Journal of biological chemistry.
[202] T. Nukiwa,et al. The activation of bovine pineal tryptophan 5‐monooxygenase , 1974, FEBS letters.
[203] A. Alzheimer. Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .